Uptake of the first oral MS therapies will result in the market value peaking at $8.4 billion in 2013

1 February 2010

Sales of multiple sclerosis disease-modifying therapies exceeded $6.0 billion in 2008 across the seven major markets (USA, Japan, France, Germany, Italy, Spain and the UK). Market research group Datamonitor anticipates the combination of continuing strong historical growth dynamics and the uptake of the first oral therapies to result in the market value peaking at $8.4 billion in 2013 before the advent of biosimilars.

The report is timely, with the recent news of two oral MS drugs vying to be first to the market - fingolimod from Swiss drug major Novartis and cladribine from Germany's Merck KGaA (The Pharma Letter January 22).

Highlights of Datamonitor findings

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK